BMRN vs. BMY: BioMarin Pharmaceutical vs. Bristol-Myers Squibb Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bristol-Myers Squibb (BMY) reports 44.01%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Bristol-Myers Squibb (BMY) reports 18.47%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Bristol-Myers Squibb (BMY) at 33.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and Bristol-Myers Squibb (BMY) at -0.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Bristol-Myers Squibb (BMY) at 1.59 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

Financial Strength Metrics

Dividends

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bristol-Myers Squibb (BMY) trades at 13.78 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

Both BioMarin Pharmaceutical (BMRN) at 2.97 and Bristol-Myers Squibb (BMY) at 2.54 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

On P/B ratio, both BioMarin Pharmaceutical (BMRN) at 1.73 and Bristol-Myers Squibb (BMY) at 5.43 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics